Clinical bottom line
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis characterized by asthma, eosinophilia, and small-to-medium vessel vasculitis. Recent advances in the management of EGPA have focused on the use of biologic therapies, particularly targeting interleukin-5 (IL-5), which plays a crucial role in eosinophil proliferation and activation. These therapies offer new hope for patients, particularly those with refractory disease or those who are unable to tolerate traditional immunosuppressive regimens.
What the evidence shows
Recent studies have highlighted the efficacy of mepolizumab, an anti-IL-5 monoclonal antibody, in reducing disease flares and corticosteroid use in patients with EGPA. A pivotal randomized controlled trial demonstrated that mepolizumab significantly increased the time to first relapse and reduced the need for maintenance corticosteroids compared to placebo (Wechsler ME, et al. N Engl J Med 2017;376:1921-1932. PMID: 28514601). This trial has been instrumental in establishing mepolizumab as a viable treatment option for EGPA.
Another study explored the use of benralizumab, which targets the IL-5 receptor, showing promising results in reducing eosinophil counts and improving clinical symptoms in EGPA patients (Steinfeld J, et al. J Allergy Clin Immunol 2019;143:2223-2232.e2. PMID: 30879990). Although further research is needed to confirm these findings, benralizumab represents a potential alternative for patients who do not respond to or cannot tolerate mepolizumab.
Additionally, rituximab, a monoclonal antibody against CD20, has been evaluated for its efficacy in EGPA, particularly in patients with ANCA-positive disease. A retrospective study suggested that rituximab may be beneficial in inducing remission in refractory cases (Moosig F, et al. Ann Rheum Dis 2013;72:1061-1064. PMID: 22975702). However, its role remains less defined compared to IL-5-targeted therapies.
Caveats and uncertainty
While biologic therapies offer new avenues for EGPA management, several caveats remain. The long-term safety and efficacy of these treatments are not fully established, and their high cost may limit accessibility. Additionally, the heterogeneity of EGPA, with varying clinical manifestations and ANCA status, complicates treatment decisions. The optimal duration of biologic therapy and the potential for combination with other immunosuppressants require further investigation.
Moreover, the majority of studies have focused on patients with refractory disease, leaving a gap in evidence for newly diagnosed patients or those with milder forms of EGPA. The impact of biologics on long-term organ damage and quality of life also warrants further study.
How this may change practice
The introduction of biologic therapies, particularly mepolizumab, has the potential to transform the management of EGPA by providing an effective treatment option with a steroid-sparing effect. This is particularly significant given the adverse effects associated with long-term corticosteroid use. Clinicians should consider these therapies for patients with refractory EGPA or those experiencing significant corticosteroid-related side effects.
As evidence continues to evolve, personalized treatment approaches based on clinical phenotype, ANCA status, and patient preferences may become more feasible. Ongoing research and real-world data will be crucial in refining treatment algorithms and optimizing patient outcomes.